$ANTH,,, Stock Talk: A look at the margins for An
Post# of 22756
(Total Views: 162)
Posted On: 06/19/2017 8:59:38 AM
$ANTH,,,
Stock Talk: A look at the margins for Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH)
June 19, 2017
Investors considering positions in Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH), might be interested in the Gross Margin Score of the company. The shares currently have a score of 5.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The low score of 5.00000 for Anthera Pharmaceuticals, Inc. indicates a top score for stability and growth.
Checking in on some valuation rankings, Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Value Composite score of 97. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 99.
After a recent scan, we can see that Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Shareholder Yield of -1.008198 and a Shareholder Yield (Mebane Faber) of -0.96670. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
At the time of writing, Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.
Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a current ERP5 Rank of 16533 . The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.
Shifting gears, we can see that Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Q.i. Value of 50.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.
Stock Talk: A look at the margins for Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH)
June 19, 2017
Investors considering positions in Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH), might be interested in the Gross Margin Score of the company. The shares currently have a score of 5.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The low score of 5.00000 for Anthera Pharmaceuticals, Inc. indicates a top score for stability and growth.
Checking in on some valuation rankings, Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Value Composite score of 97. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 99.
After a recent scan, we can see that Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Shareholder Yield of -1.008198 and a Shareholder Yield (Mebane Faber) of -0.96670. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
At the time of writing, Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.
Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a current ERP5 Rank of 16533 . The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.
Shifting gears, we can see that Anthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) has a Q.i. Value of 50.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.
(1)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼